Skip to main content
Monthly Archives

February 2022

Press Release

Calidi Biotherapeutics Announces Appointment of Alfonso “Chito” Zulueta, Former President of International for Eli Lilly, to Its Board of Directors

LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a Nevada corporation (“Calidi”), is a clinical-stage biotechnology company that is pioneering the development of stem cell-based delivery of oncolytic viruses, announced today the appointment of Alfonso "Chito" Zulueta to its Board of Directors, effective February 7, 2022. Zulueta…
Calidi Biotherapeutics
February 4, 2022
Press Release

Calidi Biotherapeutics and Edoc Acquisition Corp. Agree to Merge and Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies

-Total gross proceeds from transaction expected to be approximately $117 million prior to redemptions, combining $25 million PIPE and up to $92 million held in Edoc trust account- -Anticipated cash resources will fund Calidi’s NeuroNova and SuperNova development programs through multiple clinical milestones- -Business combination…
Calidi Biotherapeutics
February 2, 2022
Close Menu